Naringenin has a chemoprotective effect in MDA-MB-231 breast cancer cells via inhibition of caspase-3 and -9 activities.

Related Articles

Naringenin has a chemoprotective effect in MDA-MB-231 breast cancer cells via inhibition of caspase-3 and -9 activities.

Oncol Lett. 2019 Jan;17(1):1217-1222

Authors: Wang R, Wang J, Dong T, Shen J, Gao X, Zhou J

Abstract
Breast cancer is the leading cause of cancer-associated mortality in females. It has an incidence of 1.3 million per year, which increases by 2% annually. In China, breast cancer accounts for 12.2% of all cancer cases. The aim of the present study was to investigate the inhibitory effect of naringenin on triple-negative breast cancer cells. Lactate dehydrogenase and MTT assay was used to investigate the inhibitory effect of naringenin on MDA-MB-231 cell viability. Naringenin reduced the viability of MDA-MB-231 cells by arresting the cell cycle at the G2 phase. Naringenin treatment not only influenced the phase of cell cycle arrest, but also induced apoptosis in a dose-dependent manner. Naringenin treatment also resulted in a significant increase in caspase-3 and caspase-9 activity (P<0.001). Taken together, the results of the present study suggested that naringenin caused an inhibitory effect on MDA-MB-231 cells via induction of apoptosis and inhibition of caspase-3 and -9 activity.

PMID: 30655887 [PubMed]

from A via a.sfakia on Inoreader http://bit.ly/2Dl77OA